MiNK Therapeutics, Inc. (NASDAQ:INKT) Q1 2023 Earnings Convention Name Might 11, 2023 8:30 AM ET

Firm Contributors

Zack Armen – Head-Investor Relations

Jennifer Buell – President and Chief Government Officer

Marc Van Dijk – Chief Scientific Officer

Christine Klaskin – Principal Monetary and Accounting Officer

Convention Name Contributors

Emily Bodnar – H.C. Wainwright

Jack Allen – Baird

Matthew Phipps – William Blair


Women and gents, thanks for standing by. Welcome to the MiNK Therapeutics’ First Quarter 2023 Monetary Outcomes Name. I might now like to show the decision over to Zack Armen, Head of Investor Relations. Please go forward.

Zack Armen

Thanks, operator, and thanks all for becoming a member of us right now. At the moment’s name is being webcast and will probably be obtainable on our web site for replay. I’d wish to remind you that this name will comprise forward-looking statements, together with statements relating to our medical growth, regulatory and business plans in addition to time traces for knowledge launch and partnership alternatives. These statements are topic to dangers and uncertainties, and we refer you to our SEC filings for extra particulars on these dangers.

Becoming a member of me right now on the decision are Dr. Jennifer Buell, President and Chief Government Officer; Dr. Marc Van Dijk, Chief Scientific Officer; Dr. Pleasure Zhou, Head of Manufacturing; and Christine Klaskin, Principal Monetary and Accounting Officer.

Now I’d like to show the decision over to Dr. Buell to spotlight our progress from the quarter.

Jennifer Buell

Thanks very a lot, Zack. Good morning, and thanks for becoming a member of our first quarter 2023 earnings name. We’re very completely satisfied to be right here with you and to current on an thrilling first quarter, which really culminates in a major presentation on the American Affiliation of Most cancers Analysis Convention or the AACR convention simply a few weeks in the past.

Dr. Benny Carneiro, a


Source link